119 related articles for article (PubMed ID: 38664974)
1. Differential synergistic effects of palbociclib and doxorubicin on doxorubicin-resistant cancer cells with diverse tumor origins.
Yalcin GD; Mutlu P; Kazan HH; Gunduz U
J Chemother; 2024 Apr; ():1-9. PubMed ID: 38664974
[TBL] [Abstract][Full Text] [Related]
2. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
[TBL] [Abstract][Full Text] [Related]
3. Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
Soosainathan A; Iravani M; El-Botty R; Alexander J; Sourd L; Morisset L; Painsec P; Orha R; Nikitorowicz-Buniak J; Pancholi S; Haider S; Dowsett M; Marangoni E; Martin LA; Isacke CM
Cancer Res; 2024 Jan; 84(1):17-25. PubMed ID: 37801608
[TBL] [Abstract][Full Text] [Related]
4. Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer.
Katuwal NB; Kang MS; Ghosh M; Hong SD; Jeong YG; Park SM; Kim SG; Sohn J; Kim TH; Moon YW
J Exp Clin Cancer Res; 2023 Nov; 42(1):325. PubMed ID: 38017459
[TBL] [Abstract][Full Text] [Related]
5. FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.
Cheng Q; Ma Z; Shi Y; Parris AB; Kong L; Yang X
Cells; 2021 Nov; 10(11):. PubMed ID: 34831231
[TBL] [Abstract][Full Text] [Related]
6. Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy.
Lypova N; Lanceta L; Gibson A; Vega S; Garza-Morales R; McMasters KM; Chesney J; Gomez-Gutierrez JG; Imbert-Fernandez Y
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31100952
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss.
Gao Y; Shen J; Choy E; Mankin H; Hornicek F; Duan Z
Cell Oncol (Dordr); 2017 Jun; 40(3):209-218. PubMed ID: 28243976
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
Zhu X; Chen L; Huang B; Li X; Yang L; Hu X; Jiang Y; Shao Z; Wang Z
J Exp Clin Cancer Res; 2021 Apr; 40(1):122. PubMed ID: 33832512
[TBL] [Abstract][Full Text] [Related]
10. Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity.
Asby DJ; Killick-Cole CL; Boulter LJ; Singleton WG; Asby CA; Wyatt MJ; Barua NU; Bienemann AS; Gill SS
Cancer Manag Res; 2018; 10():3483-3500. PubMed ID: 30254491
[TBL] [Abstract][Full Text] [Related]
11. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
12. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
Yamamoto T; Kanaya N; Somlo G; Chen S
Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
[TBL] [Abstract][Full Text] [Related]
13. Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel.
Trapé AP; Liu S; Cortes AC; Ueno NT; Gonzalez-Angulo AM
J Cancer; 2016; 7(8):947-56. PubMed ID: 27313785
[TBL] [Abstract][Full Text] [Related]
14. The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time.
Ono M; Oba T; Shibata T; Ito KI
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3211-3224. PubMed ID: 34244855
[TBL] [Abstract][Full Text] [Related]
15. Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.
Kettner NM; Vijayaraghavan S; Durak MG; Bui T; Kohansal M; Ha MJ; Liu B; Rao X; Wang J; Yi M; Carey JPW; Chen X; Eckols TK; Raghavendra AS; Ibrahim NK; Karuturi MS; Watowich SS; Sahin A; Tweardy DJ; Hunt KK; Tripathy D; Keyomarsi K
Clin Cancer Res; 2019 Jul; 25(13):3996-4013. PubMed ID: 30867218
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.
Cheng K; Zhou Z; Chen Q; Chen Z; Cai Y; Cai H; Wu S; Gao P; Cai Y; Zhou J; Wang X; Wu Z; Peng B
Sci Rep; 2024 Apr; 14(1):8389. PubMed ID: 38600093
[TBL] [Abstract][Full Text] [Related]
17. Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.
Pandey K; Lee E; Park N; Hur J; Cho YB; Katuwal NB; Kim SK; Lee SA; Kim I; An HJ; Hwang S; Moon YW
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33504001
[TBL] [Abstract][Full Text] [Related]
18. The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter.
Fu H; Wu ZX; Lei ZN; Teng QX; Yang Y; Ashby CR; Lei Y; Lian Y; Chen ZS
Front Pharmacol; 2022; 13():861642. PubMed ID: 35350768
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer.
Lee CL; Cremona M; Farrelly A; Workman JA; Kennedy S; Aslam R; Carr A; Madden S; O'Neill B; Hennessy BT; Toomey S
Cancer Biol Ther; 2023 Dec; 24(1):2223388. PubMed ID: 37326340
[TBL] [Abstract][Full Text] [Related]
20. Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
Navarro-Yepes J; Kettner NM; Rao X; Bishop CS; Bui TN; Wingate HF; Singareeka Raghavendra A; Wang Y; Wang J; Sahin AA; Meric-Bernstam F; Hunt KK; Damodaran S; Tripathy D; Keyomarsi K
Cancer Res; 2023 Oct; 83(19):3264-3283. PubMed ID: 37384539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
